Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01830348 · ClinicalTrials.gov registry record · Phase 3

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

A Phase 3 study, sponsored by Integra LifeSciences Corporation.

Terminated
Registry status
Phase 3
Development phase
266
Enrollment target

NCT01830348: Clinical Trial Phase 3 study, sponsored by Integra LifeSciences Corporation.

NCT01830348 is a Phase 3 study that was terminated before completion, run by Integra LifeSciences Corporation. The registered enrollment target is 266 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01830348, a Phase 3 study, was terminated before completion, sponsored by Integra LifeSciences Corporation.

TERMINATED
Registry status
Phase 3
Development phase
266 participants
Enrollment target

Study Summary

The purpose of the study is to determine if DSC127 is effective in increasing incidence of complete wound closure at 10 weeks confirmed at a visit 2 weeks later when compared to the vehicle (gel without active ingredient) in subjects with diabetes mellitus (DM) who have chronic Wagner Grade 1 or 2 plantar neuropathic foot ulcers, 0.75 - 6 cm2 in size.

Primary Outcome

Primary endpoint of complete closure is assessed by the Principal Investigator at the site; ulcer measurements are calculated through tracings submitted to the Canfield system and photographs are collected as confirmation of closure via the Canfield system.

Interventions

  • DRUG DSC127
  • DRUG placebo vehicle gel

Trial Details

FieldValue
Enrollment Target 266 participants
Start Date 2013-02
Est. Completion 2015-12
Phase Phase 3
Integra LifeSciences Corporation

60 total trials

Why NCT01830348 stopped before completion

NCT01830348 is an interventional study that assigns participants to a tested intervention. The registered 266 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower).

The record links to 0 conditions, and to 2 interventions - of which DSC127 is the first listed.

NCT01830348 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01830348 about?

NCT01830348 is a clinical study titled "Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers". The purpose of the study is to determine if DSC127 is effective in increasing incidence of complete wound closure at 10 weeks confirmed at a visit 2 weeks later when compared to the vehicle (gel without active ingredient) in subjects with diabetes mellitus (DM) who have chronic Wagner Grade 1 or 2 p...

What is the current status of trial NCT01830348?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 266 participants. The study started on 2013-02. Estimated completion is 2015-12.

What interventions are being tested in trial NCT01830348?

The interventions under investigation include: DSC127 (DRUG), placebo vehicle gel (DRUG).

Who is sponsoring clinical trial NCT01830348?

This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01830348's enrollment target sits among peer trials

266 1222nd of 2000 higher than 778 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05098652 · 266 participants · NA

    Coaching Dementia Caregivers to Master Care-Resistant Behavior

  • NCT06088277 · 266 participants · NA

    Texting to Reduce Human Immunodeficiency Virus (HIV) Risk

  • NCT06261814 · 266 participants · Phase 2

    Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors

  • NCT06312124 · 266 participants · NA

    A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01830348, the US trial registry maintained by the National Library of Medicine. NCT01830348 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.